Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Head & Neck 2Sarcoma 1Other solid neoplasm 1Gynecologic 1CNS 1

Conditions

Lung Neoplasms 1Liver Neoplasms 1Hypoxia 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × fluoromisonidazole × Thoracic × Clear all
NCT02016872 2025-04-30

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

Memorial Sloan Kettering Cancer Center

Phase NA Completed
25 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01213030 2012-09-25

Clinical Evaluation of the New Hypoxia Imaging Agent HX4

Siemens Molecular Imaging

Phase 1/2 Completed
12 enrolled
GastrointestinalHead & NeckThoracic

Hypoxia, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡